Anticancer compounds

Novel compounds with specific structural features address the limitations of existing brain cancer treatments by penetrating the blood-brain barrier and effectively inhibiting tumor growth in glioblastoma.

JP7590004B2Active Publication Date: 2024-11-26THE UNIV OF SYDNEY
View PDF 16 Cites 0 Cited by

Patent Information

Application Number
JP2022127080
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2018-02-01
Filing Date
2022-08-09
Publication Date
2024-11-26
Estimated Expiration
2039-02-01

AI Technical Summary

Technical Problem

Current treatments for brain cancer, such as glioblastoma, are inadequate due to the inability of existing therapies to penetrate the blood-brain barrier and the heterogeneity of the disease, leading to limited efficacy and significant side effects.

Method used

Development of novel compounds of formula (I) that include specific alkyl, alkenyl, aryl, heteroaryl, and heterocycloalkyl groups, which can penetrate the blood-brain barrier and inhibit tubulin polymerization, potentially inducing apoptosis in cancer cells.

Benefits of technology

The compounds effectively cross the blood-brain barrier and exhibit high anti-proliferative activity against brain cancer, including glioblastoma, inducing apoptosis and inhibiting tumor growth.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007590004000021
    Figure 0007590004000021
  • Figure 0007590004000022
    Figure 0007590004000022
  • Figure 0007590004000023
    Figure 0007590004000023
Patent Text Reader

Abstract

Novel compounds are provided for the treatment of proliferative diseases such as cancer, particularly brain cancer. The present invention relates to a compound containing a heterocycloalkyl or heteroaryl group, as exemplified by the following structural formula: TIFF2022160635000022.tif26170
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • 3(5)-amino-pyrazole derivatives, processes for their preparation and their use as antitumor agents

    JP2003507329A

  • Arylmethyl-carbonylamino-thiazole derivatives and their use as antitumor agents

    JP2003507461A

  • tubulin inhibitor

    JP2007513093A

  • Substituted 2-quinolyl-oxazoles useful as pde4 inhibitors

    JP2007537300A

  • Phenylacetamides suitable as protein kinase inhibitors

    JP2008538356A